Literature DB >> 22544297

Permanent muscular sodium overload and persistent muscle edema in Duchenne muscular dystrophy: a possible contributor of progressive muscle degeneration.

M-A Weber1, A M Nagel, M B Wolf, K Jurkat-Rott, H-U Kauczor, W Semmler, F Lehmann-Horn.   

Abstract

To assess the presence and persistence of muscular edema and increased myoplasmic sodium (Na(+)) concentration in Duchenne muscular dystrophy (DMD). We examined eight DMD patients (mean age 9.5 ± 5.4 years) and eight volunteers (mean age 9.5 ± 3.2 years) with 3-tesla proton ((1)H) and (23)Na density-adapted 3D-radial MR sequences. Seven DMD patients were re-examined about 7 months later without change of therapy. The eighth DMD patient was re-examined after 5 and 11 months under medication with eplerenone. We quantified muscle edema on STIR images with background noise as reference and fatty degeneration on T1-weighted images using subcutaneous fat as reference. Na(+) was quantified by a muscular tissue Na(+) concentration (TSC) sequence employing a reference containing 51.3 mM Na(+) with 5 % agarose. With an inversion-recovery (IR) sequence, we determined mainly the myoplasmic Na(+). The normalized muscular (23)Na IR signal intensity was higher in DMD than in volunteers (n = 8, 0.75 ± 0.07 vs. 0.50 ± 0.05, p < 0.001) and persisted at second measurement (n = 7, 1st 0.75 ± 0.07, 2nd 0.73 ± 0.06, p = 0.50). When compared to volunteers (25.6 ± 2.0 mmol/l), TSC was markedly increased in DMD (38.0 ± 5.9 mmol/l, p < 0.001) and remained constant (n = 7, 1st 37.9 ± 6.4 mmol/l, 2nd 37.0 ± 4.0 mmol/l, p = 0.49). Muscular edema (15.6 ± 3.5 vs. 6.9 ± 0.7, p < 0.001) and fat content (0.48 ± 0.08 vs. 0.38 ± 0.01, p = 0.003) were elevated in DMD when compared to volunteers. This could also be confirmed during follow-up (n = 7, p = 0.91, p = 0.12). Eplerenone slightly improved muscle strength and reduced muscular sodium and edema. The permanent muscular Na(+) overload in all DMD patients is likely osmotically relevant and responsible for the persisting, mainly intracellular muscle edema that may contribute to the progressive muscle degeneration.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22544297     DOI: 10.1007/s00415-012-6512-8

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  21 in total

1.  Mechanosensitive ion channels in skeletal muscle: a link in the membrane pathology of muscular dystrophy.

Authors:  Jeffry B Lansman; Alfredo Franco-Obregón
Journal:  Clin Exp Pharmacol Physiol       Date:  2006-07       Impact factor: 2.557

2.  Leg muscle involvement in facioscapulohumeral muscular dystrophy assessed by MRI.

Authors:  David B Olsen; Peter Gideon; Tina Dysgaard Jeppesen; John Vissing
Journal:  J Neurol       Date:  2006-06-13       Impact factor: 4.849

3.  Sodium MRI using a density-adapted 3D radial acquisition technique.

Authors:  Armin M Nagel; Frederik B Laun; Marc-André Weber; Christian Matthies; Wolfhard Semmler; Lothar R Schad
Journal:  Magn Reson Med       Date:  2009-12       Impact factor: 4.668

4.  Dexamethasone-induced up-regulation of two-pore domain K+ channel genes, TASK-1 and TWIK-2, in cultured human periodontal ligament fibroblasts.

Authors:  Takahiro Yamamoto; Akito Ohara; Masanori Nishikawa; Gaku Yamamoto; Yukikazu Saeki
Journal:  In Vitro Cell Dev Biol Anim       Date:  2011-02-27       Impact factor: 2.416

5.  3D 23Na MRI of human skeletal muscle at 7 Tesla: initial experience.

Authors:  Gregory Chang; Ligong Wang; Mark E Schweitzer; Ravinder R Regatte
Journal:  Eur Radiol       Date:  2010-03-23       Impact factor: 5.315

6.  Treatment of Duchenne muscular dystrophy with ciclosporin A: a randomised, double-blind, placebo-controlled multicentre trial.

Authors:  Janbernd Kirschner; Joachim Schessl; Ulrike Schara; Bernd Reitter; Georg M Stettner; Elke Hobbiebrunken; Ekkehard Wilichowski; Günther Bernert; Simone Weiss; Florian Stehling; Gert Wiegand; Wolfgang Müller-Felber; Simone Thiele; Ulrike Grieben; Maja von der Hagen; Jürg Lütschg; Claudia Schmoor; Gabriele Ihorst; Rudolf Korinthenberg
Journal:  Lancet Neurol       Date:  2010-08-26       Impact factor: 44.182

Review 7.  Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management.

Authors:  Katharine Bushby; Richard Finkel; David J Birnkrant; Laura E Case; Paula R Clemens; Linda Cripe; Ajay Kaul; Kathi Kinnett; Craig McDonald; Shree Pandya; James Poysky; Frederic Shapiro; Jean Tomezsko; Carolyn Constantin
Journal:  Lancet Neurol       Date:  2009-11-27       Impact factor: 44.182

8.  K+-dependent paradoxical membrane depolarization and Na+ overload, major and reversible contributors to weakness by ion channel leaks.

Authors:  Karin Jurkat-Rott; Marc-André Weber; Michael Fauler; Xiu-Hai Guo; Boris D Holzherr; Agathe Paczulla; Nikolai Nordsborg; Wolfgang Joechle; Frank Lehmann-Horn
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-18       Impact factor: 11.205

Review 9.  Glucocorticoid corticosteroids for Duchenne muscular dystrophy.

Authors:  A Y Manzur; T Kuntzer; M Pike; A Swan
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23

10.  Nav1.4 deregulation in dystrophic skeletal muscle leads to Na+ overload and enhanced cell death.

Authors:  Carole Hirn; George Shapovalov; Olivier Petermann; Emmanuelle Roulet; Urs T Ruegg
Journal:  J Gen Physiol       Date:  2008-07-14       Impact factor: 4.086

View more
  21 in total

Review 1.  Quantitative techniques for musculoskeletal MRI at 7 Tesla.

Authors:  Neal K Bangerter; Meredith D Taylor; Grayson J Tarbox; Antony J Palmer; Daniel J Park
Journal:  Quant Imaging Med Surg       Date:  2016-12

Review 2.  Quantitative sodium magnetic resonance imaging of cartilage, muscle, and tendon.

Authors:  Neal K Bangerter; Grayson J Tarbox; Meredith D Taylor; Joshua D Kaggie
Journal:  Quant Imaging Med Surg       Date:  2016-12

3.  Activation of osmolyte pathways in inflammatory myopathy and Duchenne muscular dystrophy points to osmoregulation as a contributing pathogenic mechanism.

Authors:  Boel De Paepe; Jean-Jacques Martin; Sandrine Herbelet; Cecilia Jimenez-Mallebrera; Estibaliz Iglesias; Cristina Jou; Joachim Weis; Jan L De Bleecker
Journal:  Lab Invest       Date:  2016-06-20       Impact factor: 5.662

Review 4.  Treatment of dystrophin cardiomyopathies.

Authors:  Josef Finsterer; Linda Cripe
Journal:  Nat Rev Cardiol       Date:  2014-01-14       Impact factor: 32.419

5.  Atrophy of calf muscles by unloading results in an increase of tissue sodium concentration and fat fraction decrease: a 23Na MRI physiology study.

Authors:  D A Gerlach; K Schopen; P Linz; B Johannes; J Titze; J Zange; J Rittweger
Journal:  Eur J Appl Physiol       Date:  2017-05-22       Impact factor: 3.078

6.  The Donnan-dominated resting state of skeletal muscle fibers contributes to resilience and longevity in dystrophic fibers.

Authors:  Catherine E Morris; Joshua J Wheeler; Béla Joos
Journal:  J Gen Physiol       Date:  2021-11-03       Impact factor: 4.000

7.  Age-dependent changes in diastolic Ca(2+) and Na(+) concentrations in dystrophic cardiomyopathy: Role of Ca(2+) entry and IP3.

Authors:  Alfredo Mijares; Francisco Altamirano; Juan Kolster; José A Adams; José R López
Journal:  Biochem Biophys Res Commun       Date:  2014-09-19       Impact factor: 3.575

8.  Na+ dysregulation coupled with Ca2+ entry through NCX1 promotes muscular dystrophy in mice.

Authors:  Adam R Burr; Douglas P Millay; Sanjeewa A Goonasekera; Ki Ho Park; Michelle A Sargent; James Collins; Francisco Altamirano; Kenneth D Philipson; Paul D Allen; Jianjie Ma; José Rafael López; Jeffery D Molkentin
Journal:  Mol Cell Biol       Date:  2014-03-24       Impact factor: 4.272

Review 9.  The role of fibrosis in Duchenne muscular dystrophy.

Authors:  Werner Klingler; Karin Jurkat-Rott; Frank Lehmann-Horn; Robert Schleip
Journal:  Acta Myol       Date:  2012-12

Review 10.  Genetic evidence in the mouse solidifies the calcium hypothesis of myofiber death in muscular dystrophy.

Authors:  A R Burr; J D Molkentin
Journal:  Cell Death Differ       Date:  2015-06-19       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.